BCG failure leads to heightened risk of bladder cancer death

Article

Chicago-Patients with carcinoma in situ or recurrent Ta, Tis, or T1 bladdercancer are at increased risk of dying of the disease within 5 years unlessthey achieve a complete response with bacille Calmette-Guérin therapy,say researchers from the Southwest Oncology Group.

Recent Videos
DNA molecules | Image Credit: © vitstudio - stock.adobe.com
Tony Abraham, DO, MPA, a nuclear radiologist
Kelly L. Stratton, MD, FACS, answers a question during a Zoom video interview
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
DNA | Image Credit: © BillionPhotos.com - stock.adobe.com
Kyrollis Attalla, MD, an expert on prostate cancer
Related Content
© 2024 MJH Life Sciences

All rights reserved.